Research programme: proto-oncogene protein c-bcl-2 inhibitors - Oncothyreon is now called Cascadian Therapeutics/Sanford-Burnham Medical Research InstituteAlternative Names: BI-97C1; ONT-701; Sabutoclax
Latest Information Update: 16 Jul 2016
At a glance
- Originator Sanford-Burnham Medical Research Institute
- Developer Cascadian Therapeutics; Sanford Burnham Prebys Medical Discovery Institute; Virginia Commonwealth University
- Class Small molecules
- Mechanism of Action Apoptosis stimulants; Proto-oncogene protein c-bcl-2 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer